Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193805-22-000242
Filing Date
2022-02-11
Accepted
2022-02-11 16:11:11
Documents
1
Group Members
DEERFIELD MANAGEMENT COMPANY, L.P.DEERFIELD MGMT, L.P.DEERFIELD PARTNERS, L.P.

Document Format Files

Seq Description Document Type Size
1 e621298_sc13ga-werewolf.htm SC 13G/A 96543
  Complete submission text file 0001193805-22-000242.txt   97955
Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Filed by) CIK: 0001352546 (see all company filings)

Type: SC 13G/A

Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Subject) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-92515 | Film No.: 22620961
SIC: 2834 Pharmaceutical Preparations